Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
262.7 USD | -0.53% | -2.71% | -8.80% |
Apr. 17 | UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating | MT |
Apr. 16 | Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease | MT |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.